A systematic-review protocol set out ventilation, withdrawal, delirium, and safety outcomes. The supplied protocol did not report that clonidine reduced benzodiazepine requirements or improved survival.
The authors proposed searching randomized and observational studies of clonidine as an adjunct or standalone sedative in invasively ventilated patients. Duration of ventilation was the primary outcome.
Planned secondary measures included sedative dose, infusion duration, sedation level, withdrawal, delirium, hospital stay, and mortality. Hypotension, bradycardia, clonidine withdrawal, and accidental device removal were among the intended adverse outcomes.
Listing several possible benefits and harms shows what the review intended to investigate. It does not establish pooled effects, numbers of qualifying studies, or certainty of evidence. The planned inclusion of both adults and children also creates a need to consider population differences.
An adjunct that reduces one sedative amount could still introduce cardiovascular harms or fail to change ventilation duration.
Cite it as a research plan and a framework for outcome selection. It cannot support a quantitative claim that clonidine substitutes for a particular benzodiazepine dose. The paper is useful for explaining why a dose-sparing claim alone is insufficient to evaluate an ICU sedation strategy.
Original analysis of the supplied journal article, identified as PMC4635616.